Aim: Sepsis-induced lung injury remains a critical concern with significant morbidity and mortality. This study aimed to investigate the potential therapeutic role of Folic Acid in mitigating lung injury induced by sepsis while exploring its interaction with the soluble suppression of tumorigenicity 2 (sST2) protein in an experimental rat model.
Material and Methods: Rats were divided into three groups: a normal control group, a group induced with sepsis and treated with saline, and a group induced with sepsis and treated with Folic Acid (5 mg/kg). Biomarkers of oxidative stress, inflammation, respiratory gas exchange, and lung histopathology were assessed.
Results: Folic Acid administration resulted in significantly decreased Malondialdehyde (MDA) levels (p<0.01) and reduced soluble ST2 levels (p<0.05) compared to the sepsis-induced saline group. Tumor necrosis factor α (TNFα) levels were markedly reduced (p<0.001), and lung histopathology demonstrated decreased alveolar inflammation and septal thickness. Additionally, improved oxygenation (PaO2) was observed following Folic Acid treatment (p<0.05), while PaCO2 remained stable.
Conclusion: These findings suggest that Folic Acid protects against sepsis-induced lung injury, ameliorating oxidative stress, inflammation, and histopathological alterations. The modulation of soluble ST2 levels may implicate Folic Acid's role in immune regulation and potential crosstalk with the IL-33/ST2 pathway. Despite promising results, limitations inherent to animal models and the complexities of clinical translation warrant further investigation. This study highlights the potential of Folic Acid as a therapeutic intervention in sepsis-induced lung injury. It underscores the need for mechanistic studies and clinical trials to validate its effectiveness in human patients.
| Birincil Dil | İngilizce |
|---|---|
| Konular | Acil Tıp, Tıbbi Fizyoloji (Diğer) |
| Bölüm | Özgün Makaleler |
| Yazarlar | |
| Yayımlanma Tarihi | 19 Ekim 2023 |
| Kabul Tarihi | 27 Eylül 2023 |
| Yayımlandığı Sayı | Yıl 2023 Cilt: 5 Sayı: Supplement (1) - Innovations in Medicine and Healthcare in the 100th Year of the Republic |
Chief Editors
Prof. Dr. Berkant Özpolat, MD
Department of Thoracic Surgery, Ufuk University, Dr. Rıdvan Ege Hospital, Ankara, Türkiye
Editors
Prof. Dr. Sercan Okutucu, MD
Department of Cardiology, Ankara Lokman Hekim University, Ankara, Türkiye
Assoc. Prof. Dr. Süleyman Cebeci, MD
Department of Ear, Nose and Throat Diseases, Gazi University Faculty of Medicine, Ankara, Türkiye
Field Editors
Assoc. Prof. Dr. Doğan Öztürk, MD
Department of General Surgery, Manisa Özel Sarıkız Hospital, Manisa, Türkiye
Assoc. Prof. Dr. Birsen Doğanay, MD
Department of Cardiology, Ankara Bilkent City Hospital, Ankara, Türkiye
Assoc. Prof. Dr. Sonay Aydın, MD
Department of Radiology, Erzincan Binali Yıldırım University Faculty of Medicine, Erzincan, Türkiye
Language Editors
PhD, Dr. Evin Mise
Department of Work Psychology, Ankara University, Ayaş Vocational School, Ankara, Türkiye
Dt. Çise Nazım
Department of Periodontology, Dr. Burhan Nalbantoğlu State Hospital, Lefkoşa, North Cyprus
Statistics Editor
Dr. Nurbanu Bursa, PhD
Department of Statistics, Hacettepe University, Faculty of Science, Ankara, Türkiye
Scientific Publication Coordinator
Kübra Toğlu
argistyayincilik@gmail.com
Franchise Owner
Argist Yayıncılık
argistyayincilik@gmail.com
Publisher: Argist Yayıncılık
E-mail: argistyayincilik@gmail.com
Phone: 0312 979 0235
GSM: 0533 320 3209
Address: Kızılırmak Mahallesi Dumlupınar Bulvarı No:3 C-1 160 Çankaya/Ankara, Türkiye
Web: www.argistyayin.com.tr